Citadel Advisors’s Ingevity NGVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $228K | Sell |
3,200
-900
| -22% | -$61.5K | ﹤0.01% | 11137 |
|
|
2025
Q4 | $243K | Buy |
+4,100
| New | +$223K | ﹤0.01% | 10619 |
|
|
2025
Q2 | – | Sell |
-600
| Closed | -$23.8K | – | 14204 |
|
|
2025
Q1 | $23.8K | Sell |
600
-2,000
| -77% | -$88.5K | ﹤0.01% | 13020 |
|
|
2024
Q4 | $106K | Buy |
2,600
+1,400
| +117% | +$58.3K | ﹤0.01% | 11398 |
|
|
2024
Q3 | $46.8K | Sell |
1,200
-1,600
| -57% | -$63.7K | ﹤0.01% | 11985 |
|
|
2024
Q2 | $122K | Sell |
2,800
-800
| -22% | -$38.7K | ﹤0.01% | 10632 |
|
|
2024
Q1 | $172K | Sell |
3,600
-2,000
| -36% | -$89.9K | ﹤0.01% | 10561 |
|
|
2023
Q4 | $264K | Buy |
5,600
+4,700
| +522% | +$195K | ﹤0.01% | 9404 |
|
|
2023
Q3 | $42.8K | Buy |
900
+100
| +13% | +$5.46K | ﹤0.01% | 11930 |
|
|
2023
Q2 | $46.5K | Sell |
800
-1,300
| -62% | -$78K | ﹤0.01% | 11883 |
|
|
2023
Q1 | $150K | Buy |
2,100
+1,300
| +163% | +$103K | ﹤0.01% | 10635 |
|
|
2022
Q4 | $56.4K | Buy |
+800
| New | +$56.4K | ﹤0.01% | 11978 |
|
|
2022
Q2 | – | Sell |
-5,900
| Closed | -$378K | – | 13690 |
|
|
2022
Q1 | $378K | Sell |
5,900
-2,100
| -26% | -$140K | ﹤0.01% | 10050 |
|
|
2021
Q4 | $574K | Sell |
8,000
-10,900
| -58% | -$829K | ﹤0.01% | 9360 |
|
|
2021
Q3 | $1.35M | Sell |
18,900
-1,600
| -8% | -$126K | ﹤0.01% | 7373 |
|
|
2021
Q2 | $1.67M | Sell |
20,500
-2,100
| -9% | -$169K | ﹤0.01% | 7053 |
|
|
2021
Q1 | $1.71M | Buy |
22,600
+5,300
| +31% | +$386K | ﹤0.01% | 6783 |
|
|
2020
Q4 | $1.31M | Sell |
17,300
-20,100
| -54% | -$1.31M | ﹤0.01% | 6219 |
|
|
2020
Q3 | $1.85M | Buy |
37,400
+3,000
| +9% | +$169K | ﹤0.01% | 4857 |
|
|
2020
Q2 | $1.81M | Buy |
+34,400
| New | +$1.63M | ﹤0.01% | 4762 |
|
|
2020
Q1 | – | Sell |
-9,900
| Closed | -$865K | – | 9972 |
|
|
2019
Q4 | $865K | Sell |
9,900
-7,000
| -41% | -$612K | ﹤0.01% | 5860 |
|
|
2019
Q3 | $1.43M | Buy |
16,900
+4,300
| +34% | +$383K | ﹤0.01% | 5003 |
|
|
2019
Q2 | $1.32M | Buy |
12,600
+3,800
| +43% | +$382K | ﹤0.01% | 5240 |
|
|
2019
Q1 | $929K | Sell |
8,800
-2,500
| -22% | -$251K | ﹤0.01% | 5720 |
|
|
2018
Q4 | $946K | Buy |
11,300
+1,900
| +20% | +$172K | ﹤0.01% | 5399 |
|
|
2018
Q3 | $958K | Buy |
9,400
+4,400
| +88% | +$425K | ﹤0.01% | 5635 |
|
|
2018
Q2 | $404K | Buy |
5,000
+600
| +14% | +$47.7K | ﹤0.01% | 6719 |
|
|
2018
Q1 | $324K | Buy |
+4,400
| New | +$329K | ﹤0.01% | 6625 |
|
Other funds holding NGVT
VPM
VCM
SBH
SCM
Citadel Advisors's NGVT Position: Q1 2026 in Review
Citadel Advisors reduced its Ingevity (NGVT) stake by 66% in Q1 2026, selling an estimated $1.47M and leaving 10,919 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #8253.
Citadel Advisors first reported a position in NGVT in Q2 2016 and has held it in 32 quarters since. The position peaked at $12.2M in Q2 2020. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.
- Citadel Advisors held 10,919 shares of Ingevity worth $778K as of Q1 2026.
- Citadel Advisors sold 21,534 Ingevity shares in Q1 2026, an estimated $1.47M.
- Ingevity made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8253 holding.
- Citadel Advisors first reported a position in Ingevity in Q2 2016 and has held it in 32 quarters since.
- Citadel Advisors's Ingevity position peaked at $12.2M in Q2 2020.
- 307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.